Study S001316

A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT02492763
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: TERMINATED
Enrollment: 176
Start: 2015-07-27
Primary completion: 2017-04-18
Lead sponsor: Merck Sharp & Dohme LLC
Conditions: Type II Diabetes Mellitus
Interventions: DRUG:MK-8521; DRUG:Placebo; DRUG:Liraglutide; DRUG:Metformin
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:MK-8521-004

Registered primary outcomes

Change From Baseline in Hemoglobin A1C (A1C) at Week 12 [Baseline and Week 12]
Number of Participants With an Adverse Event (AE) [Up to Week 14]
Number of Participants Who Discontinued Study Treatment Due to an AE [Up to Week 12]
Number of Participants With an AE of Symptomatic Hypoglycemia [Up to Week 14]
Change From Baseline in Heart Rate at Week 12 [Baseline and Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.